ReviewTumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine2016
Biomarkers of genome instability and cancer epigenetics.
Review in Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed.
- Genome doubling as a dynamic driver of ovarian cancer evolution: insights from single-cell sequencing.Journal of ovarian research · 2025Review
- Up-regulating methylation of CAP1 promoter can promote apoptosis and inhibit migration and invasion of lung adenocarcinoma cells.European journal of medical research · 2025Article
- Polymerase Chain Reaction Chips for Biomarker Discovery and Validation in Drug Development.Micromachines · 2025Review
- Magnetic resonance imaging and deoxyribonucleic acid methylation-based radiogenomic models for survival risk stratification of glioblastoma.Medical & biological engineering & computing · 2024Article
- Pharmacogenomic and epigenomic approaches to untangle the enigma of IL-10 blockade in oncology.Expert reviews in molecular medicine · 2024Review
- Article
- Disruption of ZNF334 promotes triple-negative breast carcinoma malignancy through the SFRP1/ Wnt/β-catenin signaling axis.Cellular and molecular life sciences : CMLS · 2022Article
- B1 repetitive sequence methylation enhances wound healing of second-degree burns in rats.Biomedical reports · 2022Article
- An overview of PAX1: Expression, function and regulation in development and diseases.Frontiers in cell and developmental biology · 2022Review
- Novel GIRlncRNA Signature for Predicting the Clinical Outcome and Therapeutic Response in NSCLC.Frontiers in pharmacology · 2022Article
- Clinically relevant fusion oncogenes: detection and practical implications.Therapeutic advances in medical oncology · 2022Review
- Combined effects of cigarette smoking, DNA methyltransferase 3B genetic polymorphism, and DNA damage on lung cancer.BMC cancer · 2021Article
- Genome instability-related long non-coding RNA in clear renal cell carcinoma determined using computational biology.BMC cancer · 2021Article
- Integrated analysis of methylation-driven genes and pretreatment prognostic factors in patients with hepatocellular carcinoma.BMC cancer · 2021Article
- A novel proteomics approach to epigenetic profiling of circulating nucleosomes.Scientific reports · 2021Article
- Analysis of Methylation-driven Genes in Pancreatic Ductal Adenocarcinoma for Predicting Prognosis.Journal of Cancer · 2021Article
- Dual Role of Reactive Oxygen Species and their Application in Cancer Therapy.Journal of Cancer · 2021Review
- A Step Forward in Breast Cancer Research: From a Natural-Like Experimental Model to a Preliminary Photothermal Approach.International journal of molecular sciences · 2020Article
- Identification of DNA methylation-driven genes by integrative analysis of DNA methylation and transcriptome data in pancreatic adenocarcinoma.Experimental and therapeutic medicine · 2020Article
- Rationale and Roadmap for Developing Panels of Hotspot Cancer Driver Gene Mutations as Biomarkers of Cancer Risk.Environmental and molecular mutagenesis · 2020Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Tumorigenesis is a multistep process involving genetic and epigenetic alterations that drive somatic evolution from normal human cells to malignant derivatives. Collectively, genetic and epigenetic alterations might be combined into biomarkers for the assessment of risk, the detection of early stage tumors, and accurate tumor characterization before and after treatment. Recent efforts have provided systematic approaches to cancer genomics through the application of massive sequencing of specific tumor types. Here, we review biomarkers of genome instability and epigenetics. Cancer evolvability and adaptation emerge through genetic and epigenetic lesions of a variety of sizes and qualities-from point mutations and small insertions/deletions to large-scale chromosomal rearrangements, alterations in whole chromosome copy number, preferential allelic expression of cancer risk alleles, and mechanisms that increase tumor mutation rates. We also review specific epigenetic mechanisms that facilitate or hinder tumor adaptation, including DNA methylation, histone modification, nucleosome remodeling, transcription factor activity, and small non-coding RNAs. Given the complexity of the carcinogenic process, the challenge ahead will be to interpret disparate signals across hundreds of genes and summarize these signals into a single actionable diagnosis that translates into specific treatments. Another challenge is to refine preventive efforts through the identification of epigenetic processes that mediate increased cancer rates in individuals exposed to sources of toxic environmental stress and pollution, specially through development and early childhood.
Indexed as
Identifiers
27468720What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.